In *Escherichia coli* and related bacteria, the presence of glucose in the growth medium prevents the utilization of other carbohydrates, the so-called classic 'glucose effect' ([@B1]). Preferential utilization of different carbon sources is regulated by the phosphoenolpyruvate-dependent phosphotransferase system (PTS) which modulates the intracellular levels of cAMP ([@B2]). cAMP levels are high when cells are grown on non-PTS carbon sources such as glycerol. When grown on carbohydrates such as glucose, cAMP levels are low ([@B2],[@B3]). The activity of CRP can only be triggered by binding to cAMP ([@B3]), and therefore, in this article in order to simplify the text, the liganded CRP will be further designated as CRP, not CRP-cAMP. CRP contains three transcription activation regions and is considered as a proximal activator interacting over short distances with the major form of σ^70^-RNA polymerase (Eσ^70^), often as the promoters of sugar catabolic genes. As a CRP point mutation defective in its activation region I (ARI), CRP^H159L^ is unable to interact with the αCTD of Eσ^70^, but is still able to bind and bend DNA in a manner similar to its wild-type counterpart ([@B4]). Location of CRP-binding sites upstream of CRP-dependent promoters, their affinity for CRP and the intrinsic promoter strength determine the extent of activation ([@B3]). Detailed three-dimensional models of CRP--Eσ^70^--promoter complexes constructed by Lawson *et al*. ([@B5]) have yielded insights into how CRP binds DNA and activates transcription.

Assimilation of ammonia and acquisition of various nitrogen sources is tightly controlled in *E. coli*. A key operon, *glnALG*, encodes a key enzyme of nitrogen assimilation, glutamine synthetase (GS), and two regulatory proteins that control expression of the Ntr regulon, NtrB (also called NRII) and NtrC (also called NRI) ([@B6]). NtrC is phosphorylated by NtrB to form a hexamer ([@B7],[@B8]) of NtrC-phosphate (NtrC-P) under nitrogen-deficient growth conditions. The expression of the *glnALG* operon is controlled by tandem promoters (*glnA*p1 and *glnA*p2). *glnA*p1, located at 115 bp upstream of *glnA*p2, is a σ^70^-dependent weak promoter. Its transcription can be activated by CRP and blocked by NtrC-P ([@B9]). *glnA*p2 is transcribed by another form of RNA polymerase (Eσ^54^) and is activated by NtrC-P ([@B6],[@B10],[@B11]). Taken together, *glnA*p2 is responsible for increasing the levels of *glnA* transcription under nitrogen-deficient growth conditions ([@B11]).

Glutamine transport in *E. coli* has been shown to occur through a well-characterized high-affinity-binding-protein-dependent system (GlnHPQ) and poorly characterized low-affinity system(s). The g*lnHPQ* operon is under the control of tandem promoters (*glnH*p1p2). *glnH*p1 is σ^70^-dependent, while *glnH*p2 is σ^54^- and NtrC-P-dependent ([@B12],[@B13]).

The intracellular glutamine status is integrated and transduced by the PII signalling protein. *Escherichia coli* possesses two closely related PII paralogues, GlnB and GlnK. GlnB is produced constitutively, and it regulates the NtrB/NtrC two-component system ([@B14],[@B15]). Its non-modified form can bind NtrB, which dephosphorylates the response regulator NtrC, thus switching off transcription of *glnA*p2 ([@B16; @B17; @B18]), and of other NtrC-dependent promoters including *glnH*p2 and the *glnK* promoter ([@B19]). Low intracellular glutamine levels, signalling nitrogen deficiency, leads to uridylylation of GlnB ([@B20]). The modified complex GlnB--UMP is not able to combine with NtrB. In this state, by phosphoryl transfer, NtrC is phosphorylated by NtrB and so activates transcription ([@B17]).

For *glnA*p2, NtrC-P binds to enhancer-like sequences centred at −108 and −140 and forms an oligomer ([@B7]) to activate transcription via direct interaction with promoter bound Eσ^54^. These NtrC-P binding sites are needed for activation at low intracellular NtrC-P concentration, while high concentrations of NtrC-P can stimulate transcription at *glnA*p2 without specific binding sites ([@B6],[@B21]). In both cases, the NtrC-P must approach promoter bound Eσ^54^ from the opposite side of the DNA to which Eσ^54^ is bound ([@B22]).

Previously, we have shown that CRP down-regulates *glnA*p2 in *E. coli* ([@B9]). The latest studies suggest that this down-regulation may work through different mechanisms for different σ^54^-dependent promoters. In the case of *glnA*p2, the effect of carbon source on NtrC-dependent gene expression can be mediated through CRP-dependent glutamine uptake, thereby affecting the glutamine-sensitive UTase--PII signalling system ([@B16]). However, the mechanisms behind the CRP-dependent glutamine uptake remain unknown.

In this study, we establish that CRP influences nitrogen regulation in *E. coli* by at least two mechanisms. First, with glutamine as the nitrogen source, *glnH*p1 is activated by CRP *in vivo* and *in vitro*. Through *glnHPQ*-dependent GlnB signalling, CRP acts to decrease the amount of the phosphorylated NtrC activator, which in turn causes a decrease in *glnA*p2 expression. Second, *in vitro* CRP is recruited to a sequence upstream of the core *glnA*p2 promoter through direct interaction between the ARI of CRP and the αCTD of Eσ^54^ resulting in a reduced activity of *glnA*p2. The latter direct down-regulatory effect is evident *in vivo* when a limiting amount of ammonium is used as the nitrogen source.

MATERIALS AND METHODS
=====================

Bacterial strains and plasmids
------------------------------

Bacterial strains and plasmids used in this study are listed in [Table 1](#T1){ref-type="table"}. The entire *glnHPQ* operon in TP2339-1 was replaced by *bla* gene using pKO3 system ([@B24]). This results in strain BD4000. Table 1.Bacterial strains and plasmids used in this workStrain/plasmidRelevant characteristicsSource/reference***E. coli* strains**TP2339-1F^−^, *xyl, cya, crp-39, lacΔX74, argH1, glp*Tian *et al.* ([@B9])BD4000F^−^, *xyl, cya, crp-39, lacΔX74, argH1, glp, glnHPQ*This article**Plasmids**pKU101*glnAp2mCRP::lacZYA* fusion in pGD926Tian *et al.* ([@B9])pKU101Hentire *glnHPQ* operon inserted into pKU101This articlepKU550*glnHp1p2::lacZYA* fusion in pGD926This articlepLG339CRPpLG339 carrying *crp* under the control of the *crp* promoterKolb. A ([@B23])pLG339CRP^H159L^H159L mutant in pLG339CRPBusby. S ([@B28])pLG339ΔRSpLG339 with EcoRI/SalI internal deletionBusby. S ([@B28])[^3]

For construction of plasmid pKU550, the entire *glnH*p1p2 region together with the first 7 codons of the *glnHPQ* open reading frame (ORF) (from −289 to +63 of *glnH*p2) was amplified as a 364-bp DNA fragment by PCR using *E. coli* strain MG1655 chromosome DNA as template and 5′-CCC[AAGCTT]{.ul}GCAGCCCACCTCAACGCAC-3′ (p\#1) and 5′-CG[GGATCC]{.ul}ACTTTTAATACAGACTTCATAG-3′ (p\#2) as primers. The 364-bp DNA fragment was digested with HindIII and BamHI, cloned into pUC18 and verified by DNA sequencing. The 364-bp HindIII--BamHI DNA fragment was cloned into pGD926, and the *glnA* ORF was fused in-frame with the eigth codon of the *lacZ* reporter gene. This results in plasmid pKU550.

The entire *glnHPQ* operon was amplified by PCR using p\#1 and 5′-CCC[AAGCTT]{.ul}AATAAGACACATTGCCTG-3′ (p\#3) as primers and *E. coli* strain MG1655 chromosome DNA as template. The PCR product was restricted with HindIII, cloned into pUC18 and verified by DNA sequencing. The HindIII DNA fragment was cloned into the *glnA*p2 reporter plasmid pKU101. This results in plasmid pKU101H, which complements strain BD4100 for *glnHPQ*.

A CRP consensus-binding site was introduced into position −50.5 nucleotides upstream of the *glnA*p2 by Takara Biotechnology (Dalian) and the promoter was designed as CC-50.5 according to the location of the centre of the CRP consensus-binding site ([@B22]).

Growth media and enzyme assays
------------------------------

M63 minimal medium was prepared as previously described ([@B25]) with glycerol (0.4% w/v) as the sole carbon source, and either glutamine (0.2% w/v) or 0.2 mM ammonium as nitrogen source, in the absence/presence of exogenous cAMP (2 mM), as indicated. Cells were grown at 30°C under aerobic conditions. The growth of the cells was measured spectrophotometrically by following the optical density of the culture (OD~600~). The cultures that were used for measurements were initiated by diluting a cell suspension from an overnight-grown culture in the appropriate medium to an initial OD~600~ of 0.04--0.05. When the day-culture reached an OD~600~ between 0.8 and 1.0, β-galactosidase assays were performed as described before ([@B25]).

Primer extension and *in vivo* KMnO~4~ footprinting experiments
---------------------------------------------------------------

As described before ([@B9]), two primers (5′-CCCAGTCACGACGTTGTAAAACG-3′ (p\#4) and 5′-CAACCGTTCCGCCAGTTTGCGT-3′ (p\#5)) hybridize with the structural gene of *lacZ* (p\#4, for probing transcripts from *glnH*p1p2) and *tetR* (p\#5, for the control) on pGD926-derived plasmids, respectively, in primer extension experiments.

Protein purification, *in vitro* transcription assays and DNase I footprinting
------------------------------------------------------------------------------

As described before ([@B22]).

Real time RT-PCR assays
-----------------------

Total RNA was isolated from 5 ml *E. coli* cells (TP2339-1 with pKU101 and pLG339CRP/pLG339CRP^H159L^) at OD~600~ 0.8 using RNeasy® Mini Kit (QIAGEN). About 1.5 μg of total DNase I-treated RNA were reverse-transcribed using SuperScriptII™ RT (Invitrogen) according to the manufacturer\'s instructions. A real-time PCR was performed with each pair of primers (5′-CGGATACCGCCTTCGTTC-3′ (p\#6) and 5′-ACCGCTCTTCACAGCAACC-3′ (p\#7) that were designed for quantifying transcripts from *glnH*p1p2; 5′-CCAGAATGGTGCATCTTCAGG-3′ (p\#8) and 5′-TCAGCTCTTTAGCGATGGCAG-3′ (p\#9) were designed for quantifying transcripts from *glnH*p1; 5′-ACGGCCCCAACAGTGAAGTA-3′ (p\#10) and 5′-ACGGTCTGACGACACGCAA-3′ (p\#11) were designed for quantifying transcripts of *tetR* from pKU101 as internal control) on a MJ OPTICON® 2 using SYBR Green PCR Master Mix (Applied Biosystems). Data analyses for a relative quantification of gene expression were performed by the comparative Ct (threshold cycle) method according to the manufacturer\'s instructions. The parameter Ct is defined as the cycle number at which intensity of fluorescence (which is proportional to the quantity of DNA present in the tube during the exponential phase of the PCR) passes a fixed threshold value. The relative amount of target in two preparations is AE^(Ct\ condition\ A\ internal\ control−Ct\ condition\ A\ sample)--(Ct\ condition\ B\ internal\ control−Ct\ condition\ B\ sample)^, where conditions A and B were in the presence/absence of exogenous cAMP (2 mM), respectively, sample is *glnH*p1 or *glnH*p1p2 product, internal control is *tetR*, AE = 1.8. Experiments were performed three times.

Determination of the modification status of GlnB
------------------------------------------------

The modification status of GlnB was determined by non-denaturing polyacrylamide gel electrophoresis followed by immunodetection of GlnB using GlnB-specific antibodies as described before ([@B26]). The cell pellet was resuspended in 50 µl of ice-cold buffer (50 mM Tris-HCl pH7.4; 5 mM EDTA, 1 mM DTT and 1 mM benzamidin), added with glass beads (0.11 mm) to about the same volume as the cell pellet, and broken in a FastPrep (Thermo). Cell debris and glass beads were removed by centrifugation and the protein concentration in the supernatant was estimated as described before ([@B27]). A total of 2.5 µg protein was loaded per lane for non-denaturing PAGE. The proteins were blotted onto nitrocellulose membranes (Hybond-C Extra, Amersham) and the blots were probed with specific anti-GlnB (provided by K. Forchhammer), which were subsequently visualized using peroxidase-conjugated secondary antibodies (Promega) and DAB (Pierce) diluted 1:10 in stable peroxide substrate buffer (Pierce) as substrate.

RESULTS
=======

CRP activates the transcription of *glnH*p1 *in vitro* through its synergistic binding with Eσ^70^
--------------------------------------------------------------------------------------------------

Previous studies suggested that glutamine uptake is increased by the presence of CRP and increased extracellular glutamine elicits a nitrogen-excess signal ([@B16]). The *glnHPQ* operon encodes the high-affinity glutamine uptake system, and is under the control of σ ^70^-dependent *glnH*p1 and σ^54^- and NtrC-P-dependent *glnH*p2 ([@B12],[@B13]). Under *in vivo* conditions, *glnH*p2 is repressed by CRP (Li *et al*., unpublished data, see also [Figure 1](#F1){ref-type="fig"}). However, in a macroarray assay, we have found that the overall transcription of *glnHPQ* is activated by the presence of exogenous cAMP (2 mM, data not shown). Therefore whether *glnH*p1 transcription and the overall transcription of the *glnHPQ* operon are activated by CRP in ARI-dependent manner was studied. Figure 1.Effect of CRP and its ARI mutant CRP^H159L^ on the *glnH*p1p2 expression in the *E. coli cya crp* double mutant TP2339-1 detected by primer extension analysis. Lane 5 is G marker ladder. Cells were grown in M63 minimal medium with glycerol (0.4% w/v) as the sole carbon source, and glutamine (0.2% w/v) as nitrogen source, in the absence/presence of exogenous cAMP (2 mM).

Sequence analysis indicates that no obvious CRP-binding site can be found upstream of *glnH*p1, and DNA fragment containing *glnH*p1 cannot be retarded by CRP alone in gel shift assays (data not shown). In order to investigate the biochemical behaviour of CRP and Eσ^70^ on *glnH*p1, DNase I footprinting assays were carried out *in vitro*. The results show that in the absence of Eσ^70^, CRP cannot occupy the upstream regulatory sequences of *glnH*p1 even at high concentrations (lanes 1--5 of [Figure 2](#F2){ref-type="fig"}A). Also, in the absence of CRP, only weak occupancy of Eσ^70^ at the core promoter of *glnH*p1 is evident (lanes 6 and 10 of [Figure 2](#F2){ref-type="fig"}A; lanes 2 and 9 of [Figure 2](#F2){ref-type="fig"}B). In contrast, when wild-type CRP is present together with Eσ^70^, the binding of Eσ^70^ is strongly increased ([Figure 2](#F2){ref-type="fig"}A and B). Also, wild-type CRP is recruited by Eσ^70^ to a site centred at −61.5, organized as Class I σ^70^-promoters ([@B28]). Moreover, the above synergistic binding is abolished when wild-type CRP is replaced by its ARI mutant CRP^H159L^ ([Figure 2](#F2){ref-type="fig"}B). Figure 2.DNase I footprints of Eσ^70^ in the presence or absence of CRP and CRP^H159L^ on *glnH*p1 (non template strand). (**A**) Titration with increasing concentrations of CRP (lanes 2 and 7, 30 nM; lanes 3 and 8, 100 nM; lanes 4 and 9, 300 nM) were performed in the absence (2--4) or presence of 50 nM Eσ^70^ (lanes 7--9). Lane 11 is A + G marker ladder. The protected regions were monitored by adding increasing concentrations of CRP in the presence or absence of Eσ^70^. (**B**) Titration with increasing concentrations of CRP (lane 3, 33 nM; lane 4, 100 nM; lane 5, 300 nM) and CRP^H159L^ (lane 10, 33 nM; lane 11, 100 nM; lane 12, 300 nM) were performed in the presence of 25 nM Eσ^70^ (lanes 3--5 and 10--12). Lane 7 is A + G marker ladder. The limits of protected regions are indicated. Note that wild-type CRP is recruited to a site centred at −61.5 by Eσ^70^-RNA polymerase, which suggests a higher affinity for DNA binding of Eσ^70^ than that of CRP.

In order to investigate whether CRP can activate the transcription of *glnH*p1 in an ARI-dependent manner *in vitro*, run-off and multiple-round transcriptional assays were carried out with different concentrations of CRP or its ARI mutant CRP^H159L^. Results showed that, regardless of the concentration of Eσ^70^, wild-type CRP, but not its ARI mutant CRP^H159L^, can activate *glnH*p1 by a factor up to 6- and 14-fold in single- and multiple-round transcriptional assays, respectively. The activation factor increased when the concentration of CRP was increased ([Figure 3](#F3){ref-type="fig"}). Figure 3.Effect of CRP and its ARI mutant CRP^H159L^ on the *glnH*p1 expression *in vitro*. (**A**) multiple-round run-off assay; (**B**) single-round run-off assay.

Taken together, we have identified a naturally occurring case, where Eσ^70^ RNA polymerase binds very weakly to *glnH*p1. Binding of Eσ^70^ to *glnH*p1 recruits CRP to a degenerate site at −61.5 ('ttgTATCCacatcaTCACAcaa', which has a score of 1.44 bits, according to methods described before (([@B29]), in which 17 bits was used as the cutoff score for strong CRP-binding sites; and 10 bits as the cutoff score for weak CRP-binding sites)), and the synergistic binding between CRP and Eσ^70^ clearly helps both partners in a reciprocal manner, which results in transcriptional activation of *glnH*p1.

The overall transcription of the *glnHPQ* operon is activated by CRP *in vivo*
------------------------------------------------------------------------------

To investigate the effect of CRP on the expression of *glnHPQ in vivo*, pKU550 carrying *glnH*p1p2 fused with the *lacZ* reporter gene was transformed into *cya crp* double mutant TP2339-1 containing either pLG339CRP or pLG339CRP^H159L^. The cells were grown in M63 medium in the absence or presence of exogenous cAMP. The results showed that in the presence of exogenous cAMP, *glnH*p1p2 can be activated 3-fold by wild-type CRP. This activation was abolished when ARI mutant CRP^H159L^ replaced wild-type CRP ([Table 2](#T2){ref-type="table"}a). Table 2.Effect of CRP and its ARI mutant CRP^H159L^ on the expression of *glnH*p1p2 and *glnA*p2 in the *E. coli cya crp* double mutant TP2339-1 and *cya crp glnHPQ* triple mutant BD4000StrainCRP plasmidPromoter (plasmid)β-gal−cAMP+cAMPaTP2339-1pLG339ΔRS*glnH*p1p2(pKU550)6533 ± 3506245 ± 347TP2339-1pLG339CRP*glnH*p1p2(pKU550)6378 ± 28720190 ± 1851TP2339-1pLG339CRP^H159L^*glnH*p1p2(pKU550)6829 ± 3936416 ± 334bTP2339-1pLG339ΔRS*glnA*p2(pKU101)6650 ± 2766188 ± 265TP2339-1pLG339CRP*glnA*p2(pKU101)6588 ± 355207 ± 43TP2339-1pLG339CRP^H159L^*glnA*p2(pKU101)6423 ± 2875582 ± 255BD4000pLG339ΔRS*glnA*p2(pKU101)6478 ± 3126033 ± 283BD4000pLG339CRP*glnA*p2(pKU101)6431 ± 3053509 ± 167BD4000pLG339CRP^H159L^*glnA*p2(pKU101)6249 ± 2035163 ± 179BD4000pLG339ΔRS*glnA*p2(pKU101H)912 ± 124712 ± 76BD4000pLG339CRP*glnA*p2(pKU101H)896 ± 13020 ± 17BD4000pLG339CRP^H159L^*glnA*p2(pKU101H)869 ± 117578 ± 50cTP2339-1pLG339ΔRS*glnA*p2(pKU101)7106 ± 3126779 ± 259TP2339-1pLG339CRP*glnA*p2(pKU101)6907 ± 2963542 ± 229TP2339-1pLG339CRP^H159L^*glnA*p2(pKU101)6891 ± 3556682 ± 203BD4000pLG339ΔRS*glnA*p2(pKU101)6485 ± 2786135 ± 264BD4000pLG339CRP*glnA*p2(pKU101)6431 ± 2573509 ± 305BD4000pLG339CRP^H159L^*glnA*p2(pKU101)6249 ± 2195163 ± 249StrainCRP plasmidPromoterRelative expression− cAMP+ cAMPdTP2339-1pLG339ΔRS*glnH*p111.8 ± 0.7TP2339-1pLG339CRP*glnH*p1156.6 ± 2.1TP2339-1pLG339CRP^H159L^*glnH*p113.0 ± 1.5TP2339-1pLG339ΔRS*glnH*p1p211.0 ± 0.3TP2339-1pLG339CRP*glnH*p1p213.1 ± 0.5TP2339-1pLG339CRP^H159L^*glnH*p1p210.9 ± 0.2[^4]

In order to verify the CRP effect on *glnH*p1 and *glnH*p2 respectively, two parallel experiments were carried out. First, *in vivo* primer extension assays were carried out on both promoters from plasmid pKU550 ([Figure 1](#F1){ref-type="fig"}). Second, a more quantifiable real time RT-PCR was carried out to verify the CRP effect on both *glnH*p1 and *glnH*p1p2 transcribed directly from chromosome ([Table 2](#T2){ref-type="table"}d). In both cases, the results showed that wild-type CRP activates *glnH*p1, but represses *glnH*p2. In contrast, CRP^H159L^ does not affect the expression of *glnH*p1 or *glnH*p2. Quantitatively, the results obtained from real time RT-PCR correlate well with the results obtained from β-galactosidase assays (compare [Table 2](#T2){ref-type="table"}d with 2a). Therefore, it seems that the CRP effect on *glnH*p1p2 is somewhat similar to that obtained with *glnA*p1p2, where CRP also activates σ^70^-dependent *glnA*p1, and represses σ^54^-dependent *glnA*p2 ([@B9]). However, they are different in at least two ways. First, the overall output is different. In this case, CRP causes a 3--4-fold decrease of overall expression for *glnA* ([@B9]), but a 3-fold increase for *glnH* ([Table 2](#T2){ref-type="table"}a and d). Second, it is known that a classical CRP-binding site is located upstream of the *glnA*p1 promoter ([@B10],[@B30]), essential for CRP-dependent activation of *glnA*p1 ([@B9]). In contrast, no obvious CRP-binding site can be found upstream of *glnH*p1. CRP activates the transcription of *glnH*p1 *in vitro* through its synergistic binding with Eσ^70^ ([Figure 2](#F2){ref-type="fig"}).

The CRP effect is maximized through *glnHPQ*-mediated glutamine uptake
----------------------------------------------------------------------

The above results, together with the results obtained from Maheswaran and Forchhammer ([@B16]), suggest that CRP increases expression of the *glnHPQ* operon, which in turn, increases glutamine uptake. It has been proposed that, as a consequence, the intracellular glutamine level is increased, and so elicits a nitrogen-excess signal. In this case, the GlnB signalling process leads to the dephosphorylation of NtrC, and subsequent de-activation of NtrC-P-dependent promoters such as *glnA*p2 and *glnH*p2 ([@B16],[@B31]).

To further investigate the above proposal, the *glnHPQ* operon was deleted from *cya* and *crp* double mutant TP2339-1 to give a triple mutant strain designated BD4000. The expression of *glnA*p2 (pKU101) was measured in the carbon poor medium in the presence of glutamine, in the presence/absence of cAMP. The results showed that the repression effect of wild-type CRP on the expression of *glnA*p2 is reduced from 30-fold to 2-fold upon deletion of *glnHPQ*. As control, the ARI mutant CRP^H159L^ has no such repression effect ([Table 2](#T2){ref-type="table"}b). The *glnHPQ* mutant could still grow in the carbon-poor medium in the presence of glutamine, where glutamine uptake might be carried out by the low-affinity systems ([@B32]) (also see [Figure 4](#F4){ref-type="fig"}). Figure 4.Effect of CRP and its ARI mutant CRP^H159L^ on the uridylylation status of GlnB in the *E. coli cya crp* double mutant TP2339-1 and *cya crp glnHPQ* triple mutant BD4000. All strains (lanes 1--8) were grown in M63 minimal medium with glycerol (0.4% w/v) as the sole carbon source, and glutamine (0.2% w/v) as nitrogen source, in the absence/presence of exogenous cAMP (2 mM). TP2339-1 was grown in nitrogen-sufficient medium with 40 mM ammonium as control (lane 9).

To complement BD4000 for the *glnHPQ* operon, and minimize the artificial effects from genetic manipulation, a new *glnA*p2 reporter low copy number plasmid carrying the entire *glnHPQ* operon was constructed (designed as pKU101H), and used for the following assays. In this case, the CRP/cAMP effect on the expression of *glnA*p2 was investigated. Results indicated that when BD4000 was complemented by pKU101H, the CRP-mediated repression effect could be restored from 2-fold to 50-fold by wild-type CRP, while its ARI mutant CRP^H159L^ had no such effect ([Table 2](#T2){ref-type="table"}b). We also noticed that such restoration could only be observed when cells grown in M63-minimum medium supplemented with glutamine, but not with ammonium, as the sole nitrogen source, indicating that the restoration effect requires physical transport of glutamine into the cells, rather than the sole enhancement of *glnHPQ* expression ([Table 2](#T2){ref-type="table"}c).

Maheswaran and Forchhammer ([@B16]) showed that deuridylylation of GlnB is a direct consequence of glutamine addition to cAMP-treated cells, which agrees with their proposal that cAMP increases the intracellular glutamine level when glutamine is used as the sole nitrogen source. In this study, similar assays were done with both TP2339-1 and BD4000 strains ([Figure 4](#F4){ref-type="fig"}). The cells were grown in the presence of glutamine as the sole nitrogen source except the control (lane 9). As shown in the figure, in the absence of wild-type CRP (lanes 1, 3 and 4) or in the absence of GlnHPQ (lanes 5--8), GlnB is in its highly uridylylated state. By contrast, more than 80% of GlnB is in its deuridylylated state in the presence of both wild-type CRP and GlnHPQ (lane 2). As control, we showed that GlnB is mostly deuridylylated in the presence of 40 mM ammonium (lane 9). Taken together, the above results show that the GlnHPQ-mediated GlnB signalling is regulated by CRP. The intracellular concentration of glutamine is increased to a nitrogen-excess level by the GlnHPQ transport system in the presence of CRP and GlnB is deuridylylated in this case. As a consequence, NtrC is dephosphorylated and the expression of *glnA*p2 is decreased in the presence of CRP.

It is interesting to note that when the *glnHPQ* operon is deleted, the carbon source/cAMP effect remains, although it is reduced dramatically ([Table 2](#T2){ref-type="table"}b). This result indicates that there is another repression mechanism, which might not be related to the glutamine uptake. To further investigate this possibility, ammonium was used to replace the glutamine as the sole nitrogen source. Results showed that wild-type CRP, but not its ARI mutant CRP^H159L^, still represses *glnA*p2 by a factor of 2-fold in both TP2339-1 and BD4000 ([Table 2](#T2){ref-type="table"}c). This result supports the notion that alternative mechanism(s) may exist for CRP-mediated repression on *glnA*p2.

CRP repressed the expression of *glnA*p2 directly *in vitro*
------------------------------------------------------------

To investigate whether CRP can repress *glnA*p2 directly, multiple-round transcriptional assays were carried out with different concentrations of CRP or its ARI mutant CRP^H159L^. Results showed that wild-type CRP can repress the transcriptional activity of *glnA*p2 by a factor of 2-fold. Moreover, when wild-type CRP was replaced by its ARI mutant CRP^H159L^, the repression effect was abolished ([Figure 5](#F5){ref-type="fig"}). Also, this repression effect can be increased to 10-fold, when NtrC^S160F^ (a constitutive active form of NtrC with a lower activity compared to NtrC-P) was used to replace wild-type NtrC-P ([Figure 5](#F5){ref-type="fig"}), indicating that repression would be greater when a partially active form of NtrC exists in the cell ([@B33]). Figure 5.Effect of CRP and its ARI mutant CRP^H159L^ on the *glnA*p2 expression *in vitro*. Wild-type CRP and NtrC^S160F^ (▴) CRP and NtrC-P (▪), and CRP^H159L^ and NtrC-P (♦), were used in the multiple-round transcriptional assays. The activity of *glnA*p2 with Eσ^54^+NtrC-P/NtrC^S160F^ in the absence of CRP or CRP^H159L^ was taken as 100%.

To investigate the mechanism of the ARI-dependent repression effect on *glnA*p2, DNase I footprinting assays were carried out *in vitro*. In the absence of Eσ^54^, CRP or its ARI mutant CRP^H159L^ cannot occupy the upstream sequence of *glnA*p2 (lanes 9 and 10 of [Figure 6](#F6){ref-type="fig"}). On the other hand, in the absence of CRP, full occupancy of Eσ^54^ on the core promoter of *glnA*p2 was observed (lane 13 of [Figure 6](#F6){ref-type="fig"}). When CRP is present together with Eσ^54^, two additional protection regions were observed upstream of the binding site of Eσ^54^. In contrast, when ARI mutant CRP^H159L^ was used in the assay, these additional protections were not evident (compare lanes 11 and 12 of [Figure 6](#F6){ref-type="fig"}). Figure 6.DNase I footprints of Eσ^54^ in the presence or absence of CRP and CRP^H159L^ on CC-50.5 (A CRP consensus-binding site was introduced into position −50.5 nucleotides upstream of the *glnA*p2) or wild-type *glnA*p2. CRP, CRP^H159L^ and Eσ^54^, when added, were present at a final concentration of 50 nM. Lanes 1 and 8 are A+G marker ladders. The limits of protected regions are indicated. On *glnA*p2, only wild-type CRP can bind co-operatively with Eσ^54^ and the protection region is comparable to the one on CC-50.5. The locations of specific protected or hypersensitive bands are different on the two templates due to the difference of the sequence of CRP-binding sites. The hypersensitive band due to the CRP-binding on *glnA*p2 is marked by arrow. The protection of αCTD binding, which is co-operative only with wild-type CRP, is similar on both *glnA*p2 and CC-50.5 (lanes 5 and 12). These results strongly support that the relative orientation between CRP and Eσ^54^ is similar on *glnA*p2 and CC-50.5.

The two additional protection regions are from −42 to −61 and from −63 to −71. According to the location and size of the protected regions, it is possible that CRP binds and bends DNA from −42 to −61 and αCTD of Eσ^54^ binds DNA upstream. The binding and bending centre for CRP is at −51.5. Previous research by Huo *et al*. ([@B22]) had shown that when CRP was located at −50.5 on *glnA*p2, CRP and Eσ^54^ lie on the same face of DNA helix. Presumably the DNA bending induced by CRP, places NtrC-P far from the activator-accessible face of the closed complex and in turn represses the expression of *glnA*p2. The contact between αCTD and the upstream DNA region supports the view that DNA bending exists. Taken together, CRP was recruited by Eσ^54^ in an ARI-dependent manner and repressed NtrC-P mediated activation of *glnA*p2 directly.

DISCUSSION
==========

In this study, we have shown that there are two novel mechanisms for CRP to mediate nitrogen regulation. In one mechanism CRP can affect the PII-mediated signal transduction pathway, hence causing deactivation of σ^54^-dependent *gln* promoters (for instance, *glnA*p2). Specifically, *in vitro* experiments show that *glnH*p1 promoter is a Class I-like CRP-dependent promoter. Through ARI--αCTD interaction, CRP and Eσ^70^ bind synergistically to *glnH*p1 to form the closed complex ([Figure 2](#F2){ref-type="fig"}). The synergy between CRP and Eσ^70^ activates *glnH*p1 ([Table 2](#T2){ref-type="table"}d). Despite *glnH*p2 repression ([Figure 1](#F1){ref-type="fig"}), the overall enhanced *glnHPQ* expression (∼3-fold, see [Table 2](#T2){ref-type="table"}a and d) leads to increased glutamine uptake, leading to PII-UMP deuridylylation ([Figure 4](#F4){ref-type="fig"}) and shuts down the Ntr response in consequence. The other mechanism is that CRP can change the topological arrangement of Eσ^54^, NtrC-phosphate and *glnA*p2 promoter, thus directly repressing the *glnA*p2 promoter ([Figure 5](#F5){ref-type="fig"}). Specifically, CRP can be recruited to the *glnA*p2 promoter at position −51.5 through ARI--αCTD interactions. This recruitment leads to DNA bending by CRP at −51.5, and hence inhibits the *glnA*p2 promoter activity ([Figure 6](#F6){ref-type="fig"}). Taken together, our study reveals the mechanisms of CRP-mediated nitrogen regulation and presents two novel regulatory linkages between carbon metabolism and nitrogen assimilation in *E. coli*. The signal transduction pathway shown in our study illuminates the regulatory link between PII and carbon regulation ([@B31]). Although glutamine can be used as a sole carbon source supporting slow growth ([@B34]), it is surprising to find that the transport of glutamine is controlled by both global-carbon and global-nitrogen signal transduction pathways.

The dynamic range of expression of *glnHPQ* from the 'off' state to the 'on' state is greater when it has one σ^54^-dependent promoter and one σ^70^ promoter. The σ^54^-dependent promoter may be able to give higher levels of transcription than the σ^70^-dependent one could, but still is repressible by carbon status through action of CRP. In the presence of glutamine, the product of these two tandem promoters provides a novel feed-back to the *glnA*p2 expression, through PII-NtrBC in the genetic cascade controlling nitrogen assimilation, other than GlnK-AmtB ([@B35]). The complicated regulatory mechanisms described above are involved in a related physiological pathway. To manage the nitrogen deficiency, *E. coli* uses NtrC/Nac system to scavenge for nitrogen-containing compounds as a first line of defense against nitrogen starvation ([@B36]). To manage the carbon deficiency, *E. coli* uses CRP to activate various carbon source transporter systems ([@B37; @B38; @B39]) (You *et al*. unpublished data). Results obtained from this study indicate that CRP also accelerates transport of glutamine, even in the absence of glutamine in the medium, and represses the synthesis of glutamine to efficiently balance the carbon metabolism and nitrogen assimilation. When the relevant key signals in the promoter sequences are searched for *in silico*, the CRP inhibitory effect on glutamine biosynthesis appears to be also encountered in other enterobacteria (such as *Klebsiella pneumoniae, Shigella flexneri, Enterobacter gergoviae, Erwinia carotovora* and *Salmonella enterica* serovar Typhimurium), although the details of the regulation might differ. Interestingly in *S. typhimurium*, a *bona fide* CRP-binding site ('caaTGTGAaagttgGCACAgat', which has a score of 10.99 bits, according to methods described before ([@B29])) is found centred at −27.5 upstream of *glnA*p2. This suggests that competition may occur between CRP and Eσ^54^ for binding to the promoter region. As there is no Nac protein found yet in *S. typhimurium* ([@B40]), it would be interesting to know if a tighter regulatory linkage exists.

As a global regulator, CRP is estimated to interact at ≈200 regulatory regions in *E. coli.* Zheng *et al*. ([@B41]) had revealed 152 hitherto unknown CRP regulons involved in energy production, amino acid metabolism, nucleotide metabolism and ion transport systems by run-off transcription/microarray analysis (ROMA). Moreover, Grainger *et al*. ([@B42]) had shown that CRP also interacts with thousands of weaker sites across the whole *E. coli* chromosome other than CRP-binding sites at known CRP regulated promoters by chromatin immunoprecipitation and high-density microarrays (ChIP-chip). We demonstrate that, physiologically, CRP tends to use weak affinity DNA-binding sites for transcriptional activation or repression by a regulated recruitment mechanism ([@B43]). It would be interesting to see if cross-talk between carbon metabolism and the other major areas of metabolism are mediated through mechanisms similar to those identified in our studies.
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